CG Oncology, Inc. (CGON) Price & Analysis

Compare

171 Followers

CGON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$14.80 - $40.47

Previous Close$30.46

Volume740.02K

Average Volume (3M)911.29K

Market Cap

$2.05B

Enterprise Value$1.18B

Total Cash (Recent Filing)$688.43M

Total Debt (Recent Filing)$1.04M

Price to Earnings (P/E)―

Beta1.90

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding76,225,310

10 Day Avg. Volume915,280

30 Day Avg. Volume911,289

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.57

Enterprise Value/Revenue1.78K

Enterprise Value/Gross Profit1.80K

Enterprise Value/Ebitda-8.77

Forecast

1Y Price Target

$56.14

Price Target Upside115.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Litigation OutcomeCG Oncology wins lawsuit against ANI Pharmaceuticals, resulting in no royalty payments owed for cretostimogene.

Market OpportunityThe current valuation is significantly disconnected from the underlying fundamentals, suggesting potential for growth.

Pipeline ProgressUpcoming milestones for CG Oncology include topline data releases and filing for regulatory approval, indicating active progress in their pipeline.

Product DifferentiationCreto is meaningfully differentiated by its durability and safety data, which supports further upside for creto in additional indications and combinations with other therapies.

Bears Say

Investor SentimentShort interest in CG Oncology is relatively high at 24% of the float, which may indicate skepticism from some investors.

CG Oncology, Inc. News

CG Oncology announces Delaware Superior Court ruling in its favor

CG Oncology (CGON) (CG) announced that a jury in the Superior Court of the State of Delaware unanimously...

10d ago

ANIP

CGON

CG Oncology price target lowered to $53 from $68 at RBC Capital

RBC Capital lowered the firm’s price target on CG Oncology (CGON) to $53 from $68 and keeps an...

23d ago

CGON

CG Oncology resumed with a Buy at Goldman Sachs

Goldman Sachs resumed coverage of CG Oncology (CGON) with a Buy rating and $40 price target The firm...

29d ago

CGON

Positive Outlook for CG Oncology: Legal Victory and Promising Milestones Drive Buy Rating

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc.. The associated price...

9d ago

CGON

CG Oncology Appoints Interim CFO After Resignation

CG Oncology, Inc. ( ($CGON) ) has issued an announcement. CG Oncology, Inc. announced that its Chief Financial...

28d ago

CGON

CG Oncology price target raised to $56 from $52 at Morgan Stanley

Morgan Stanley raised the firm’s price target on CG Oncology (CGON) to $56 from $52 and keeps an...

2M ago

CGON

CG Oncology Holds 2025 Annual Stockholders Meeting

CG Oncology, Inc. ( ($CGON) ) just unveiled an update. On June 5, 2025, CG Oncology, Inc. held...

2M ago

CGON

Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment

Brian Cheng, an analyst from J.P. Morgan, maintained the Buy rating on CG Oncology, Inc. (CGON – Research...

2M ago

CGON

CG Oncology Advances Bladder Cancer Therapies in Q1 2025

CG Oncology, Inc. ( ($CGON) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

CGON

Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on CGON stock, giving a Buy rating today....

3M ago

CGON

CG Oncology, Inc.: Promising Outlook with Strong Clinical Performance and Strategic BLA Submission

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating...

3M ago

CGON

Promising Prospects for CG Oncology’s Cretostimogene in NMIBC Treatment: Superior Efficacy and Strategic Expansion

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report)...

3M ago

CGON

CG Oncology reports Q1 EPS (45c), consensus (37c)

Reports Q1 revenue $52k, consensus $123.95k. “In 2025, we made further progress advancing cretostimogene monotherapy as a bladder-sparing...

3M ago

CGON

Apple downgraded, Reddit upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

AZO

BDX

CGON FAQ

What was CG Oncology, Inc.’s price range in the past 12 months?

CG Oncology, Inc. lowest stock price was $14.80 and its highest was $40.47 in the past 12 months.

What is CG Oncology, Inc.’s market cap?

CG Oncology, Inc.’s market cap is $2.05B.

When is CG Oncology, Inc.’s upcoming earnings report date?

CG Oncology, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 102 days.

How were CG Oncology, Inc.’s earnings last quarter?

CG Oncology, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.082.

Is CG Oncology, Inc. overvalued?

According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CG Oncology, Inc. pay dividends?

CG Oncology, Inc. does not currently pay dividends.

What is CG Oncology, Inc.’s EPS estimate?

CG Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CG Oncology, Inc. have?

CG Oncology, Inc. has 76,225,310 shares outstanding.

What happened to CG Oncology, Inc.’s price movement after its last earnings report?

CG Oncology, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -3.895%.

Which hedge fund is a major shareholder of CG Oncology, Inc.?

Currently, no hedge funds are holding shares in CGON

CG Oncology, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-16.57%

Trailing 12-Months

Asset Growth

25.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CG Oncology, Inc.

CG Oncology, Inc. (CGON) is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of urologic cancers. The company is dedicated to addressing unmet medical needs by advancing its proprietary oncolytic immunotherapy platform, which utilizes genetically modified viruses to selectively replicate within and destroy cancer cells while sparing normal tissue. CG Oncology's pipeline includes lead product candidates targeting bladder cancer and other solid tumors.

CG Oncology, Inc. (CGON) Earnings & Revenues

Historic Earnings Reports

CGON Stock 12 Month Forecast

Average Price Target

$56.14

▲(115.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","52":"$52","83":"$83","36.5":"$36.5","67.5":"$67.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,36.5,52,67.5,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.35,30.630769230769232,34.91153846153846,39.19230769230769,43.473076923076924,47.753846153846155,52.034615384615385,56.315384615384616,60.59615384615385,64.87692307692308,69.15769230769232,73.43846153846154,77.71923076923076,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.35,28.641538461538463,30.933076923076925,33.22461538461538,35.51615384615385,37.80769230769231,40.09923076923077,42.39076923076923,44.68230769230769,46.973846153846154,49.26538461538462,51.55692307692308,53.848461538461535,{"y":56.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.35,26.092307692307692,25.834615384615386,25.576923076923077,25.31923076923077,25.06153846153846,24.803846153846155,24.546153846153846,24.28846153846154,24.03076923076923,23.773076923076925,23.515384615384615,23.25769230769231,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.58,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >